ACTINIUM PHARMACEUTICALS, INC. Finance Lease, Liability, to be Paid, Year Two
ACTINIUM PHARMACEUTICALS, INC. (ATNM) had Finance Lease, Liability, to be Paid, Year Two of $11.00 thousand as of 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Notes › Commitment and Contingencies › Finance Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo · last filed 2025-03-31
- 2024-12-31: Finance Lease, Liability, to be Paid, Year Two $11.00K.
- 2024-03-31: Finance Lease, Liability, to be Paid, Year Two $11.00K.
- 2023-09-30: Finance Lease, Liability, to be Paid, Year Two $11.00K.
| Period end | Finance Lease, Liability, to be Paid, Year Two |
|---|---|
| 2024-12-31 | $11.00K 10-K · filed 2025-03-31 |
| 2024-03-31 | $11.00K 10-Q · filed 2024-04-26 |
| 2023-09-30 | $11.00K 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |